Current and evolving approaches for improving the oral permeability of BCS Class III or analogous molecules

Abstract The Biopharmaceutics Classification System (BCS) classifies pharmaceutical compounds based on their aqueous solubility and intestinal permeability. The BCS Class III compounds are hydrophilic molecules (high aqueous solubility) with low permeability across the biological membranes. While these compounds are pharmacologically effective, poor absorption due to low permeability becomes the rate-limiting step in achieving adequate bioavailability. Several approaches have been explored and utilized for improving the permeability profiles of these compounds. The approaches include traditional methods such as prodrugs, permeation enhancers, ion-pairing, etc., as well as relatively modern approaches such as nanoencapsulation and nanosizing. The most recent approaches include a combination/hybridization of one or more traditional approaches to improve drug permeability. While some of these approaches have been extremely successful, i.e. drug products utilizing the approach have progressed through the USFDA approval for marketing; others require further investigation to be applicable. This article discusses the commonly studied approaches for improving the permeability of BCS Class III compounds.

[1]  M. Kang,et al.  Synthesis and Physicochemical Evaluation of Entecavir-Fatty Acid Conjugates in Reducing Food Effect on Intestinal Absorption , 2018, Molecules.

[2]  D. K. Tripathy,et al.  Multi-response optimization of machining process parameters for powder mixed electro-discharge machining of H-11 die steel using grey relational analysis and topsis , 2017 .

[3]  S. Maeda,et al.  Potential of D-Octaarginine-Linked Polymers as an in Vitro Transfection Tool for Biomolecules. , 2015, Bioconjugate chemistry.

[4]  Joo-Youp Lee,et al.  Herceptin conjugated PLGA-PHis-PEG pH sensitive nanoparticles for targeted and controlled drug delivery. , 2015, International journal of pharmaceutics.

[5]  B. Glaser,et al.  Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. , 2015, The Journal of clinical endocrinology and metabolism.

[6]  S. Kannan,et al.  Emerging concepts in dendrimer‐based nanomedicine: from design principles to clinical applications , 2014, Journal of internal medicine.

[7]  Prakash Khadka,et al.  Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability , 2014 .

[8]  P. Rahman,et al.  Rhamnolipid biosurfactants—past, present, and future scenario of global market , 2014, Front. Microbiol..

[9]  Martin G Pomper,et al.  State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[10]  Y. Matsumura The drug discovery by nanomedicine and its clinical experience. , 2014, Japanese journal of clinical oncology.

[11]  M. Perelman,et al.  Chitosan: a promising safe and immune-enhancing adjuvant for intranasal vaccines. , 2014, Human vaccines & immunotherapeutics.

[12]  A. Tolcher,et al.  Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer , 2013, Cancer Chemotherapy and Pharmacology.

[13]  Y. Liu,et al.  Understanding the toxicity of carbon nanotubes. , 2013, Accounts of chemical research.

[14]  Jun Qian,et al.  Up-regulating Blood Brain Barrier Permeability of Nanoparticles via Multivalent Effect , 2013, Pharmaceutical Research.

[15]  Y. Byun,et al.  Enhanced oral absorption of ibandronate via complex formation with bile acid derivative. , 2013, Journal of pharmaceutical sciences.

[16]  G. Amidon,et al.  Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue. , 2013, Molecular pharmaceutics.

[17]  A. Attama,et al.  Lipid Nanoparticulate Drug Delivery Systems: A Revolution in Dosage Form Design and Development , 2012 .

[18]  M. Emeje,et al.  Nanotechnology in Drug Delivery , 2012 .

[19]  L. Perioli,et al.  Influence of the Nanocomposite MgAl-HTlc on Gastric Absorption of Drugs: In Vitro and Ex Vivo Studies , 2012, Pharmaceutical Research.

[20]  Y. Barenholz Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[21]  David J Brayden,et al.  CriticalSorb™ Promotes Permeation of Flux Markers Across Isolated Rat Intestinal Mucosae and Caco-2 Monolayers , 2012, Pharmaceutical Research.

[22]  S. Melmed,et al.  Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. , 2012, The Journal of clinical endocrinology and metabolism.

[23]  T. Yen,et al.  Opening of epithelial tight junctions and enhancement of paracellular permeation by chitosan: microscopic, ultrastructural, and computed-tomographic observations. , 2012, Molecular pharmaceutics.

[24]  B. Aungst Absorption Enhancers: Applications and Advances , 2012, The AAPS Journal.

[25]  Alexander M. Seifalian,et al.  Toxicology and clinical potential of nanoparticles , 2011, Nano today.

[26]  Nicole F Steinmetz,et al.  Applications of viral nanoparticles in medicine. , 2011, Current opinion in biotechnology.

[27]  Preeti K. Suresh,et al.  Ion-paired Drug Delivery: An Avenue for Bioavailability Improvement , 2011 .

[28]  J. Benoit,et al.  Strategies for the nanoencapsulation of hydrophilic molecules in polymer-based nanoparticles. , 2011, Biomaterials.

[29]  E. Gundogdu,et al.  Assessment of fexofenadine hydrochloride permeability and dissolution with an anionic surfactant using Caco-2 cells. , 2011, Die Pharmazie.

[30]  M. Sisani,et al.  Preformulation studies on host–guest composites for oral administration of BCS class IV drugs: HTlc and furosemide , 2011 .

[31]  H. Hoyer,et al.  An oral oligonucleotide delivery system based on a thiolated polymer: Development and in vitro evaluation. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[32]  M. Qiao,et al.  [The characterisitics of temperature/pH sensitive block copolymer micelles in vitro]. , 2011, Yao xue xue bao = Acta pharmaceutica Sinica.

[33]  H. Frey,et al.  Partially quarternized amino functional poly(methacrylate) terpolymers: versatile drug permeability modifiers. , 2011, Biomacromolecules.

[34]  H. Takeuchi,et al.  A mucoadhesive nanoparticulate system for the simultaneous delivery of macromolecules and permeation enhancers to the intestinal mucosa. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[35]  T. Marbury,et al.  Enhanced Absorption of Nasulin™, an Ultrarapid-Acting Intranasal Insulin Formulation, Using Single Nostril Administration in Normal Subjects , 2011, Journal of diabetes science and technology.

[36]  M. Varma,et al.  Targeting intestinal transporters for optimizing oral drug absorption. , 2010, Current drug metabolism.

[37]  G. Amidon,et al.  Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir. , 2010, Molecular pharmaceutics.

[38]  P. Kesharwani,et al.  Dendrimer toxicity: Let's meet the challenge. , 2010, International journal of pharmaceutics.

[39]  R. Jankowiak,et al.  Electrochemically deposited metal nanoparticles for enhancing the performance of microfluidic MEMS in biochemical analysis , 2009 .

[40]  C. Cho,et al.  Studies on the formation of hydrophobic ion-pairing complex of alendronate , 2009, Archives of pharmacal research.

[41]  G. Amidon,et al.  Chemical and enzymatic stability of amino acid prodrugs containing methoxy, ethoxy and propylene glycol linkers. , 2009, Molecular pharmaceutics.

[42]  S. Franzen,et al.  Targeting cancer with 'smart bombs': equipping plant virus nanoparticles for a 'seek and destroy' mission. , 2009, Nanomedicine.

[43]  D. Kerr,et al.  Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. , 2009, International journal of oncology.

[44]  E. Miele,et al.  Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer , 2009, International journal of nanomedicine.

[45]  G. Sharma,et al.  Design of Biodegradable Nanoparticles for Oral Delivery of Doxorubicin: In vivo Pharmacokinetics and Toxicity Studies in Rats , 2009, Pharmaceutical Research.

[46]  H. Kubinyi Prodrugs: Challenges and Rewards. Parts 1 and 2. Edited by Valentino J. Stella, Ronald T. Borchardt, Michael J. Hageman, Reza Oliyai, Hans Maag, and Jefferson W. Tilley. , 2008 .

[47]  M. Socinski,et al.  Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[48]  L. Fang,et al.  Effect of ion‐pairing and enhancers on scutellarin skin permeability , 2008, The Journal of pharmacy and pharmacology.

[49]  S. Nie,et al.  Therapeutic Nanoparticles for Drug Delivery in Cancer , 2008, Clinical Cancer Research.

[50]  Tycho Heimbach,et al.  Prodrugs: design and clinical applications , 2008, Nature Reviews Drug Discovery.

[51]  Duane E. Prasuhn,et al.  Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[52]  J. Hamman,et al.  Targeting Receptors, Transporters and Site of Absorption to Improve Oral Drug Delivery , 2007, Drug target insights.

[53]  R. Neubert,et al.  Influence of absorption enhancers on the pharmacokinetic properties of non-oral beta-lactam-cefpirom using the rabbit (Chinchilla) in vivo model. , 2006, International journal of pharmaceutics.

[54]  Marianne Manchester,et al.  Canine parvovirus-like particles, a novel nanomaterial for tumor targeting , 2006, Journal of nanobiotechnology.

[55]  C. Mant,et al.  Effect of anionic ion-pairing reagent hydrophobicity on selectivity of peptide separations by reversed-phase liquid chromatography. , 2005, Journal of chromatography. A.

[56]  Meindert Danhof,et al.  Targeting liposomes with protein drugs to the blood-brain barrier in vitro. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[57]  A. Bernkop‐Schnürch,et al.  Development of a mucoadhesive and permeation enhancing buccal delivery system for PACAP (pituitary adenylate cyclase-activating polypeptide). , 2005, International journal of pharmaceutics.

[58]  K. Ulbrich,et al.  Polymeric micellar pH-sensitive drug delivery system for doxorubicin. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[59]  Hans Lennernäs,et al.  The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension , 2005, The Journal of pharmacy and pharmacology.

[60]  R. Barrett,et al.  XP13512 [(±)-1-([(α-Isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane Acetic Acid], A Novel Gabapentin Prodrug: I. Design, Synthesis, Enzymatic Conversion to Gabapentin, and Transport by Intestinal Solute Transporters , 2004, Journal of Pharmacology and Experimental Therapeutics.

[61]  Liang-Yin Chu,et al.  Preparation of glucose-sensitive microcapsules with a porous membrane and functional gates. , 2004, Colloids and surfaces. B, Biointerfaces.

[62]  V. Ambrogi,et al.  Potential prodrugs of non-steroidal anti-inflammatory agents for targeted drug delivery to the CNS. , 2004, European journal of medicinal chemistry.

[63]  C. Teng,et al.  Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate. , 2004, Journal of pharmaceutical sciences.

[64]  A. Bernkop‐Schnürch,et al.  Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: thiomer/GSH systems. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[65]  K. Beaumont,et al.  Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. , 2003, Current drug metabolism.

[66]  E. Peira,et al.  Influence of ion pairing on topical delivery of retinoic acid from microemulsions. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[67]  G. Hardee,et al.  Effect of sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in pigs. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[68]  James E Polli,et al.  Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[69]  Indu Pal Kaur,et al.  Ocular Preparations: The Formulation Approach , 2002, Drug development and industrial pharmacy.

[70]  B. W. Barry,et al.  Novel mechanisms and devices to enable successful transdermal drug delivery. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[71]  A. R. Kulkarni,et al.  Biodegradable polymeric nanoparticles as drug delivery devices. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[72]  S. Howells,et al.  Novel Nanoparticles for Pulmonary Drug Administration , 2001, Journal of drug targeting.

[73]  M. Roberts,et al.  Effect of Ion Pairing with Alkylamines on the In‐vitro Dermal Penetration and Local Tissue Disposition of Salicylates , 2000, The Journal of pharmacy and pharmacology.

[74]  J. Mcgregor,et al.  Soluble biodegradable polymer-based cytokine gene delivery for cancer treatment. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[75]  J Dressman,et al.  Improving drug solubility for oral delivery using solid dispersions. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[76]  Y. Rojanasakul,et al.  Oxygen Radical-Mediated Pulmonary Toxicity Induced by Some Cationic Liposomes , 2000, Pharmaceutical Research.

[77]  J. Hadgraft,et al.  The dermal delivery of lignocaine: influence of ion pairing. , 2000, International journal of pharmaceutics.

[78]  Gordon L. Amidon,et al.  Targeted prodrug design to optimize drug delivery , 2000, AAPS PharmSci.

[79]  R. Cavalli,et al.  Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). , 1999, Pharmacological research.

[80]  V. Dodane,et al.  Effect of chitosan on epithelial permeability and structure. , 1999, International journal of pharmaceutics.

[81]  P. Couvreur,et al.  Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[82]  Y. Kalia,et al.  Mechanisms of oral permeation enhancement , 1997 .

[83]  E. De Clercq,et al.  Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine , 1996, Antimicrobial agents and chemotherapy.

[84]  Lisbeth Illum,et al.  Effect of Chitosan on the Permeability of Monolayers of Intestinal Epithelial Cells (Caco-2) , 1994, Pharmaceutical Research.

[85]  J. C. Martin,et al.  Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). , 1994, Journal of medicinal chemistry.

[86]  William A. Lee,et al.  Oral Bioavailability of the Antiretroviral Agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) from Three Formulations of the Prodrug Bis(pivaloyloxymethyl)-PMEA in Fasted Male Cynomolgus Monkeys , 1994, Pharmaceutical Research.

[87]  N. Orentreich,et al.  The possibility of lidocaine ion pair absorption through excised hairless mouse skin. , 1992, Skin pharmacology : the official journal of the Skin Pharmacology Society.

[88]  L. Beauchamp,et al.  Amino Acid Ester Prodrugs of Acyclovir , 1992 .

[89]  M. Nitschke,et al.  Antimicrobial activity of rhamnolipids against Listeria monocytogenes and their synergistic interaction with nisin , 2013 .

[90]  G. Plosker Pegylated Liposomal Doxorubicin , 2012, Drugs.

[91]  Jonathan M. Miller The Impact of Molecular Complexation on Intestinal Membrane Permeation. , 2009 .

[92]  Xiaorong He Integration of Physical, Chemical, Mechanical, and Biopharmaceutical Properties in Solid Oral Dosage Form Development , 2009 .

[93]  V. Stella Prodrug Approaches to Enhancing the Oral Delivery of Poorly Permeable Drugs , 2007 .

[94]  V. Torchilin Multifunctional nanocarriers. , 2006, Advanced drug delivery reviews.

[95]  S. Frokjaer,et al.  Intestinal solute carriers: an overview of trends and strategies for improving oral drug absorption. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[96]  G. Plosker,et al.  Adefovir dipivoxil: a review of its use in chronic hepatitis B. , 2003, Drugs.

[97]  G L Amidon,et al.  Absorption of peptide and peptidomimetic drugs. , 1994, Annual review of pharmacology and toxicology.

[98]  D Tomlinson,et al.  Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS. , 1994, Clinical oncology (Royal College of Radiologists (Great Britain)).

[99]  G. Amidon,et al.  Design of prodrugs for improved gastrointestinal absorption by intestinal enzyme targeting. , 1985, Methods in enzymology.

[100]  Y. Kawashima,et al.  International Journal of Nanomedicine Dovepress Hydrophobic Ion Pairing of an Insulin-sodium Deoxycholate Complex for Oral Delivery of Insulin , 2022 .